William Pao
Faculty Member
Last active: 3/24/2014


None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W (2014) Clin Cancer Res 20(9): 2264-75
    › Primary publication · 24599935 (PubMed) · PMC4008689 (PubMed Central)
  2. Patterns and processes of somatic mutations in nine major cancers. Jia P, Pao W, Zhao Z (2014) BMC Med Genomics : 11
    › Primary publication · 24552141 (PubMed) · PMC3942057 (PubMed Central)
  3. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. Wang R, Pan Y, Li C, Zhang H, Garfield D, Li Y, Ye T, Hu H, Luo X, Li H, Zhang Y, Zhang J, Zhou X, Shen L, Pao W, Sun Y, Chen H (2014) J Thorac Oncol 9(6): 760-8
    › Primary publication · 24481316 (PubMed)
  4. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W (2013) Clin Cancer Res 19(24): 6696-702
    › Primary publication · 24345920 (PubMed) · PMC3880773 (PubMed Central)
  5. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Wang Q, Jia P, Li F, Chen H, Ji H, Hucks D, Dahlman KB, Pao W, Zhao Z (2013) Genome Med 5(10): 91
    › Primary publication · 24112718 (PubMed) · PMC3971343 (PubMed Central)
  6. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, Niu D, Nacht M, Petter RC, Westlin W, Lin K, Jaw-Tsai S, Raponi M, Van Dyke T, Etter J, Weaver Z, Pao W, Singh J, Simmons AD, Harding TC, Allen A (2013) Cancer Discov 3(12): 1404-15
    › Primary publication · 24065731 (PubMed) · PMC4048995 (PubMed Central)
  7. Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. Hosgood HD, Pao W, Rothman N, Hu W, Pan YH, Kuchinsky K, Jones KD, Xu J, Vermeulen R, Simko J, Lan Q (2013) Respir Med 107(11): 1755-62
    › Primary publication · 24055406 (PubMed) · PMC3848251 (PubMed Central)
  8. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Red Brewer M, Yun CH, Lai D, Lemmon MA, Eck MJ, Pao W (2013) Proc Natl Acad Sci U S A 110(38): E3595-604
    › Primary publication · 24019492 (PubMed) · PMC3780914 (PubMed Central)
  9. Two co-existing germline mutations P53 V157D and PMS2 R20Q promote tumorigenesis in a familial cancer syndrome. Wang Z, Sun Y, Gao B, Lu Y, Fang R, Gao Y, Xiao T, Liu XY, Pao W, Zhao Y, Chen H, Ji H (2014) Cancer Lett 342(1): 36-42
    › Primary publication · 23981578 (PubMed) · PMC3981830 (PubMed Central)
  10. Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer. Yu HA, Pao W (2013) Nat Rev Clin Oncol 10(10): 551-2
    › Primary publication · 23959269 (PubMed) · PMC4665630 (PubMed Central)
  11. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W (2013) Genome Res 23(9): 1434-45
    › Primary publication · 23733853 (PubMed) · PMC3759720 (PubMed Central)
  12. Further advances in genetically informed lung cancer medicine. Nebhan C, Pao W (2013) J Thorac Oncol 8(5): 521-2
    › Primary publication · 23584291 (PubMed) · PMC3640560 (PubMed Central)
  13. Characteristics of lung cancers harboring NRAS mutations. Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA, Pao W (2013) Clin Cancer Res 19(9): 2584-91
    › Primary publication · 23515407 (PubMed) · PMC3643999 (PubMed Central)
  14. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ (2013) Clin Cancer Res 19(8): 2240-7
    › Primary publication · 23470965 (PubMed) · PMC3630270 (PubMed Central)
  15. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, Sosman JA (2013) AJR Am J Roentgenol 200(3): 475-83
    › Primary publication · 23436834 (PubMed) · PMC3652983 (PubMed Central)
  16. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. Ohashi K, Maruvka YE, Michor F, Pao W (2013) J Clin Oncol 31(8): 1070-80
    › Primary publication · 23401451 (PubMed) · PMC3589701 (PubMed Central)
  17. Maximizing the benefits of off-target kinase inhibitor activity. Red Brewer M, Pao W (2013) Cancer Discov 3(2): 138-40
    › Primary publication · 23400472 (PubMed)
  18. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Yeh P, Chen H, Andrews J, Naser R, Pao W, Horn L (2013) Clin Cancer Res 19(7): 1894-901
    › Primary publication · 23344264 (PubMed) · PMC4121886 (PubMed Central)
  19. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, Luo X, Wang L, Li H, Zhang Y, Li F, Lu Y, Lu Q, Xu J, Garfield D, Shen L, Ji H, Pao W, Sun Y, Chen H (2012) J Clin Oncol 30(35): 4352-9
    › Primary publication · 23150706 (PubMed)
  20. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Lan Q, Hsiung CA, Matsuo K, Hong YC, Seow A, Wang Z, Hosgood HD, Chen K, Wang JC, Chatterjee N, Hu W, Wong MP, Zheng W, Caporaso N, Park JY, Chen CJ, Kim YH, Kim YT, Landi MT, Shen H, Lawrence C, Burdett L, Yeager M, Yuenger J, Jacobs KB, Chang IS, Mitsudomi T, Kim HN, Chang GC, Bassig BA, Tucker M, Wei F, Yin Z, Wu C, An SJ, Qian B, Lee VH, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Kim JH, Gao YT, Tsai YH, Jung YJ, Guo H, Hu Z, Hutchinson A, Wang WC, Klein R, Chung CC, Oh IJ, Chen KY, Berndt SI, He X, Wu W, Chang J, Zhang XC, Huang MS, Zheng H, Wang J, Zhao X, Li Y, Choi JE, Su WC, Park KH, Sung SW, Shu XO, Chen YM, Liu L, Kang CH, Hu L, Chen CH, Pao W, Kim YC, Yang TY, Xu J, Guan P, Tan W, Su J, Wang CL, Li H, Sihoe AD, Zhao Z, Chen Y, Choi YY, Hung JY, Kim JS, Yoon HI, Cai Q, Lin CC, Park IK, Xu P, Dong J, Kim C, He Q, Perng RP, Kohno T, Kweon SS, Chen CY, Vermeulen R, Wu J, Lim WY, Chen KC, Chow WH, Ji BT, Chan JK, Chu M, Li YJ, Yokota J, Li J, Chen H, Xiang YB, Yu CJ, Kunitoh H, Wu G, Jin L, Lo YL, Shiraishi K, Chen YH, Lin HC, Wu T, Wu YL, Yang PC, Zhou B, Shin MH, Fraumeni JF, Lin D, Chanock SJ, Rothman N (2012) Nat Genet 44(12): 1330-5
    › Primary publication · 23143601 (PubMed) · PMC4169232 (PubMed Central)
  21. Translating genomic information into clinical medicine: lung cancer as a paradigm. Levy MA, Lovly CM, Pao W (2012) Genome Res 22(11): 2101-8
    › Primary publication · 23019146 (PubMed) · PMC3483539 (PubMed Central)
  22. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. Foo J, Chmielecki J, Pao W, Michor F (2012) J Thorac Oncol 7(10): 1583-93
    › Primary publication · 22982659 (PubMed) · PMC3693219 (PubMed Central)
  23. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansén S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Jänne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, Meyerson M (2012) Cell 150(6): 1107-20
    › Primary publication · 22980975 (PubMed) · PMC3557932 (PubMed Central)
  24. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W (2012) Cancer Discov 2(10): 922-33
    › Primary publication · 22956644 (PubMed) · PMC3473100 (PubMed Central)
  25. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus HU, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Grütter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DA, Snijders PJ, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Brustugun OT, Lund-Iversen M, Sänger J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Büttner R, Wolf J, Nürnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, Thomas RK (2012) Nat Genet 44(10): 1104-10
    › Primary publication · 22941188 (PubMed) · PMC4915822 (PubMed Central)
  26. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, Küppers R, Thomas RK (2012) Clin Cancer Res 18(17): 4682-90
    › Primary publication · 22912387 (PubMed)
  27. Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives. Wang Q, Xia J, Jia P, Pao W, Zhao Z (2013) Brief Bioinform 14(4): 506-19
    › Primary publication · 22877769 (PubMed) · PMC3713712 (PubMed Central)
  28. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Johnson ML, Sima CS, Chaft J, Paik PK, Pao W, Kris MG, Ladanyi M, Riely GJ (2013) Cancer 119(2): 356-62
    › Primary publication · 22810899 (PubMed) · PMC3966555 (PubMed Central)
  29. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W (2012) Cancer Discov 2(9): 791-7
    › Primary publication · 22798288 (PubMed) · PMC3449158 (PubMed Central)
  30. Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. Yatabe Y, Pao W, Jett JR (2012) J Thorac Oncol 7(5): 775-6
    › Primary publication · 22722783 (PubMed)
  31. Consensus rules in variant detection from next-generation sequencing data. Jia P, Li F, Xia J, Chen H, Ji H, Pao W, Zhao Z (2012) PLoS One 7(6): e38470
    › Primary publication · 22715385 (PubMed) · PMC3371040 (PubMed Central)
  32. Screening for germline EGFR T790M mutations through lung cancer genotyping. Oxnard GR, Miller VA, Robson ME, Azzoli CG, Pao W, Ladanyi M, Arcila ME (2012) J Thorac Oncol 7(6): 1049-52
    › Primary publication · 22588155 (PubMed) · PMC3354706 (PubMed Central)
  33. A new target for therapy in squamous cell carcinoma of the lung. Ohashi K, Pao W (2011) Cancer Discov 1(1): 23-4
    › Primary publication · 22586316 (PubMed)
  34. New approaches to targeted therapy in lung cancer. Pao W (2012) Proc Am Thorac Soc 9(2): 72-3
    › Primary publication · 22550248 (PubMed) · PMC3359104 (PubMed Central)
  35. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W (2012) PLoS One 7(4): e35309
    › Primary publication · 22536370 (PubMed) · PMC3335021 (PubMed Central)
  36. NGS catalog: A database of next generation sequencing studies in humans. Xia J, Wang Q, Jia P, Wang B, Pao W, Zhao Z (2012) Hum Mutat 33(6): E2341-55
    › Primary publication · 22517761 (PubMed) · PMC4431973 (PubMed Central)
  37. Chipping away at the lung cancer genome. Pao W, Hutchinson KE (2012) Nat Med 18(3): 349-51
    › Primary publication · 22395697 (PubMed)
  38. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Lovly CM, Pao W (2012) Sci Transl Med 4(120): 120ps2
    › Primary publication · 22323827 (PubMed)
  39. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, Luo X, Ye T, Wang R, Hu H, Li H, Wang L, Pao W, Chen H (2012) Clin Cancer Res 18(7): 1947-53
    › Primary publication · 22317764 (PubMed) · PMC3319848 (PubMed Central)
  40. ROS1 rearrangements define a unique molecular class of lung cancers. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ (2012) J Clin Oncol 30(8): 863-70
    › Primary publication · 22215748 (PubMed) · PMC3295572 (PubMed Central)
  41. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. Chmielecki J, Pietanza MC, Aftab D, Shen R, Zhao Z, Chen X, Hutchinson K, Viale A, Kris MG, Stout T, Miller V, Rizvi N, Pao W (2012) J Thorac Oncol 7(2): 434-42
    › Primary publication · 22173702 (PubMed) · PMC3261336 (PubMed Central)
  42. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. Li C, Fang R, Sun Y, Han X, Li F, Gao B, Iafrate AJ, Liu XY, Pao W, Chen H, Ji H (2011) PLoS One 6(11): e28204
    › Primary publication · 22140546 (PubMed) · PMC3227646 (PubMed Central)
  43. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML (2011) J Natl Compr Canc Netw : S1-32; quiz S33
    › Primary publication · 22138009 (PubMed)
  44. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. Li C, Sun Y, Fang R, Han X, Luo X, Wang R, Pan Y, Hu H, Zhang Y, Pao W, Shen L, Ji H, Chen H (2012) J Thorac Oncol 7(1): 85-9
    › Primary publication · 22071781 (PubMed)
  45. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F (2011) Mol Pharm 8(6): 2069-79
    › Primary publication · 21995722 (PubMed) · PMC3230244 (PubMed Central)
  46. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, Rauh D, Pao W, Thomas RK (2011) Clin Cancer Res 17(23): 7394-401
    › Primary publication · 21948233 (PubMed) · PMC3382103 (PubMed Central)
  47. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. Chmielecki J, Peifer M, Viale A, Hutchinson K, Giltnane J, Socci ND, Hollis CJ, Dean RS, Yenamandra A, Jagasia M, Kim AS, Davé UP, Thomas RK, Pao W (2012) Genes Chromosomes Cancer 51(1): 54-65
    › Primary publication · 21938754 (PubMed)
  48. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. Azzoli CG, Temin S, Aliff T, Baker S, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G, American Society of Clinical Oncology (2011) J Clin Oncol 29(28): 3825-31
    › Primary publication · 21900105 (PubMed) · PMC3675703 (PubMed Central)
  49. EGFR mutant lung cancer. Gong Y, Pao W (2012) Curr Top Microbiol Immunol : 59-81
    › Primary publication · 21866438 (PubMed)
  50. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB (2011) Neuro Oncol 13(12): 1364-9
    › Primary publication · 21865399 (PubMed) · PMC3223088 (PubMed Central)
  51. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. Riely GJ, Johnson ML, Medina C, Rizvi NA, Miller VA, Kris MG, Pietanza MC, Azzoli CG, Krug LM, Pao W, Ginsberg MS (2011) J Thorac Oncol 6(8): 1435-7
    › Primary publication · 21847063 (PubMed)
  52. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, Riely GJ, Pao W, Kris MG, Ladanyi M, Azzoli CG, Miller VA (2011) Clin Cancer Res 17(19): 6322-8
    › Primary publication · 21831955 (PubMed) · PMC3186869 (PubMed Central)
  53. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G, Pao W (2012) Eur Respir J 39(2): 366-72
    › Primary publication · 21778168 (PubMed)
  54. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W (2011) Clin Cancer Res 17(17): 5530-7
    › Primary publication · 21775534 (PubMed) · PMC3166976 (PubMed Central)
  55. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, Kris MG, Inoue A, Ladanyi M, Miller VA, Michor F, Pao W (2011) Sci Transl Med 3(90): 90ra59
    › Primary publication · 21734175 (PubMed) · PMC3500629 (PubMed Central)
  56. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. Johnson ML, Riely GJ, Rizvi NA, Azzoli CG, Kris MG, Sima CS, Ginsberg MS, Pao W, Miller VA (2011) J Thorac Oncol 6(6): 1128-31
    › Primary publication · 21623279 (PubMed) · PMC3230574 (PubMed Central)
  57. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W (2011) Cancer Res 71(14): 4920-31
    › Primary publication · 21613408 (PubMed) · PMC3138877 (PubMed Central)
  58. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Rizvi NA, Rusch V, Pao W, Chaft JE, Ladanyi M, Miller VA, Krug LM, Azzoli CG, Bains M, Downey R, Flores R, Park B, Singh B, Zakowski M, Heelan RT, Shen R, Kris MG (2011) Clin Cancer Res 17(10): 3500-6
    › Primary publication · 21558399 (PubMed) · PMC3261615 (PubMed Central)
  59. Molecular predictors of response to chemotherapy in non-small cell lung cancer. Andrews J, Yeh P, Pao W, Horn L (2011) Cancer J 17(2): 104-13
    › Primary publication · 21427554 (PubMed)
  60. A bioinformatics workflow for variant peptide detection in shotgun proteomics. Li J, Su Z, Ma ZQ, Slebos RJ, Halvey P, Tabb DL, Liebler DC, Pao W, Zhang B (2011) Mol Cell Proteomics 10(5): M110.006536
    › Primary publication · 21389108 (PubMed) · PMC3098595 (PubMed Central)
  61. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL (2011) Proc Natl Acad Sci U S A 108(12): 5021-6
    › Primary publication · 21385943 (PubMed) · PMC3064360 (PubMed Central)
  62. T4 or MI? Sengsayadeth S, Montgomery J, Pao W (2011) J Thorac Oncol 6(3): 632
    › Primary publication · 21317744 (PubMed)
  63. New driver mutations in non-small-cell lung cancer. Pao W, Girard N (2011) Lancet Oncol 12(2): 175-80
    › Primary publication · 21277552 (PubMed)
  64. How genetically engineered mouse tumor models provide insights into human cancers. Politi K, Pao W (2011) J Clin Oncol 29(16): 2273-81
    › Primary publication · 21263096 (PubMed) · PMC3731923 (PubMed Central)
  65. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, Kris MG, Ginsberg MS, Pao W, Miller VA, Riely GJ (2011) Clin Cancer Res 17(8): 2521-7
    › Primary publication · 21248303 (PubMed)
  66. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, Kris MG, Pao W, Miller VA, Ladanyi M (2011) Clin Cancer Res 17(5): 1169-80
    › Primary publication · 21248300 (PubMed) · PMC3070951 (PubMed Central)
  67. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL, Iafrate AJ, Pao W (2011) J Mol Diagn 13(1): 74-84
    › Primary publication · 21227397 (PubMed) · PMC3070558 (PubMed Central)
  68. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansén S, Rauh D, Baessmann I, Altmüller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, Engel-Riedel W, Ludwig C, Petersen I, Sänger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nürnberg P, Perner S, Thomas RK (2010) Sci Transl Med 2(62): 62ra93
    › Primary publication · 21160078 (PubMed) · PMC3990281 (PubMed Central)
  69. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D'Angelo SP, Kris MG, Shen R, Zheng J, Azzoli CG (2011) J Thorac Oncol 6(3): 569-75
    › Primary publication · 21150674 (PubMed) · PMC3778680 (PubMed Central)
  70. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA (2011) Clin Cancer Res 17(6): 1616-22
    › Primary publication · 21135146 (PubMed) · PMC3060283 (PubMed Central)
  71. Genetically informed lung cancer medicine. Pao W, Iafrate AJ, Su Z (2011) J Pathol 223(2): 230-40
    › Primary publication · 21125677 (PubMed)
  72. Highly active antitumor therapy (HAATT) for epidermal growth factor receptor-mutant lung cancer. Chmielecki J, Pao W (2010) Clin Cancer Res 16(22): 5371-3
    › Primary publication · 21062927 (PubMed)
  73. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Pao W, Chmielecki J (2010) Nat Rev Cancer 10(11): 760-74
    › Primary publication · 20966921 (PubMed) · PMC3072803 (PubMed Central)
  74. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, Riely GJ, Heelan RT, Arcila ME, Miller VA (2010) J Thorac Oncol 5(10): 1623-9
    › Primary publication · 20871262 (PubMed) · PMC4020424 (PubMed Central)
  75. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H, Ji H (2010) J Clin Oncol 28(30): 4616-20
    › Primary publication · 20855837 (PubMed) · PMC2974342 (PubMed Central)
  76. [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. Azzoli CG, Baker S, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2010) Zhongguo Fei Ai Za Zhi 13(3): 171-89
    › Primary publication · 20681066 (PubMed) · PMC6136061 (PubMed Central)
  77. Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Chmielecki J, Peifer M, Jia P, Socci ND, Hutchinson K, Viale A, Zhao Z, Thomas RK, Pao W (2010) Nucleic Acids Res 38(20): 6985-96
    › Primary publication · 20587502 (PubMed) · PMC2978357 (PubMed Central)
  78. Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. Gao B, Sun Y, Zhang J, Ren Y, Fang R, Han X, Shen L, Liu XY, Pao W, Chen H, Ji H (2010) J Thorac Oncol 5(8): 1130-5
    › Primary publication · 20559149 (PubMed) · PMC4009449 (PubMed Central)
  79. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Zhao B, Oxnard GR, Moskowitz CS, Kris MG, Pao W, Guo P, Rusch VM, Ladanyi M, Rizvi NA, Schwartz LH (2010) Clin Cancer Res 16(18): 4647-53
    › Primary publication · 20534736 (PubMed) · PMC2940965 (PubMed Central)
  80. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB (2010) J Thorac Oncol 5(7): 1048-53
    › Primary publication · 20512075 (PubMed) · PMC2893286 (PubMed Central)
  81. Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Redente EF, Dwyer-Nield LD, Merrick DT, Raina K, Agarwal R, Pao W, Rice PL, Shroyer KR, Malkinson AM (2010) Am J Pathol 176(6): 2972-85
    › Primary publication · 20431028 (PubMed) · PMC2877857 (PubMed Central)
  82. Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. Sun YH, Fang R, Gao B, Han XK, Zhang JH, Pao W, Chen HQ, Ji HB (2010) Acta Pharmacol Sin 31(5): 647-8
    › Primary publication · 20418893 (PubMed) · PMC3990499 (PubMed Central)
  83. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB (2010) J Neurooncol 99(2): 283-6
    › Primary publication · 20146086 (PubMed) · PMC3973736 (PubMed Central)
  84. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Girard N, Lou E, Azzoli CG, Reddy R, Robson M, Harlan M, Orlow I, Yatabe Y, Nafa K, Ladanyi M, Viale A, Kris MG, Riely G, Miller V, Klein RJ, Matsuo K, Pao W (2010) Clin Cancer Res 16(2): 755-63
    › Primary publication · 20068085 (PubMed) · PMC2808124 (PubMed Central)
  85. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. Solomon SB, Zakowski MF, Pao W, Thornton RH, Ladanyi M, Kris MG, Rusch VW, Rizvi NA (2010) AJR Am J Roentgenol 194(1): 266-9
    › Primary publication · 20028932 (PubMed) · PMC3676673 (PubMed Central)
  86. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA (2010) J Clin Oncol 28(2): 357-60
    › Primary publication · 19949011 (PubMed) · PMC3870288 (PubMed Central)
  87. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA (2010) Nat Genet 42(1): 77-82
    › Primary publication · 19946270 (PubMed) · PMC4002225 (PubMed Central)
  88. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. Azzoli CG, Baker S, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G, American Society of Clinical Oncology (2009) J Clin Oncol 27(36): 6251-66
    › Primary publication · 19917871 (PubMed) · PMC2793036 (PubMed Central)
  89. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Girard N, Shen R, Guo T, Zakowski MF, Heguy A, Riely GJ, Huang J, Lau C, Lash AE, Ladanyi M, Viale A, Antonescu CR, Travis WD, Rusch VW, Kris MG, Pao W (2009) Clin Cancer Res 15(22): 6790-9
    › Primary publication · 19861435 (PubMed) · PMC2783876 (PubMed Central)
  90. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, Zakowski MF, Frankel S, Peifer M, Thomas RK, Ladanyi M, Pao W (2009) PLoS One 4(10): e7273
    › Primary publication · 19806209 (PubMed) · PMC2752171 (PubMed Central)
  91. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, Getlik M, Heukamp LC, Ansén S, Zander T, Beroukhim R, Kashkar H, Shokat KM, Sellers WR, Rauh D, Orr C, Hoeflich KP, Friedman L, Wong KK, Pao W, Thomas RK (2009) Proc Natl Acad Sci U S A 106(43): 18351-6
    › Primary publication · 19805051 (PubMed) · PMC2757399 (PubMed Central)
  92. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Girard N, Deshpande C, Lau C, Finley D, Rusch V, Pao W, Travis WD (2009) Am J Surg Pathol 33(12): 1752-64
    › Primary publication · 19773638 (PubMed) · PMC5661977 (PubMed Central)
  93. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W (2009) J Clin Invest 119(10): 3000-10
    › Primary publication · 19759520 (PubMed) · PMC2752070 (PubMed Central)
  94. Lung cancer in never smokers: molecular profiles and therapeutic implications. Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, Schwartz AG, Vahakangas KH, Samet JM (2009) Clin Cancer Res 15(18): 5646-61
    › Primary publication · 19755392 (PubMed) · PMC2950319 (PubMed Central)
  95. Integration of molecular profiling into the lung cancer clinic. Pao W, Kris MG, Iafrate AJ, Ladanyi M, Jänne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson BE, Lynch TJ (2009) Clin Cancer Res 15(17): 5317-22
    › Primary publication · 19706816 (PubMed)
  96. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Girard N, Ostrovnaya I, Lau C, Park B, Ladanyi M, Finley D, Deshpande C, Rusch V, Orlow I, Travis WD, Pao W, Begg CB (2009) Clin Cancer Res 15(16): 5184-90
    › Primary publication · 19671847 (PubMed) · PMC2892178 (PubMed Central)
  97. EML4-ALK: honing in on a new target in non-small-cell lung cancer. Horn L, Pao W (2009) J Clin Oncol 27(26): 4232-5
    › Primary publication · 19667260 (PubMed) · PMC6955145 (PubMed Central)
  98. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman JM, Major J, Sander C, Seshan VE, Zakowski MF, Rusch V, Pao W, Gerald W, Ladanyi M (2009) Oncogene 28(31): 2773-83
    › Primary publication · 19525976 (PubMed) · PMC2722688 (PubMed Central)
  99. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, Mischel PS, Sander C, Taylor B, Schultz N, Major J, Heguy A, Fang F, Mellinghoff IK, Chan TA (2009) Proc Natl Acad Sci U S A 106(23): 9435-40
    › Primary publication · 19478061 (PubMed) · PMC2687998 (PubMed Central)
  100. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Girard N, Deshpande C, Azzoli CG, Rusch VW, Travis WD, Ladanyi M, Pao W (2010) Chest 137(1): 46-52
    › Primary publication · 19376842 (PubMed)
  101. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK (2009) Cancer Res 69(8): 3256-61
    › Primary publication · 19351834 (PubMed) · PMC2849653 (PubMed Central)
  102. KRAS mutations in non-small cell lung cancer. Riely GJ, Marks J, Pao W (2009) Proc Am Thorac Soc 6(2): 201-5
    › Primary publication · 19349489 (PubMed)
  103. Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Zakowski MF, Hussain S, Pao W, Ladanyi M, Ginsberg MS, Heelan R, Miller VA, Rusch VW, Kris MG (2009) Arch Pathol Lab Med 133(3): 470-7
    › Primary publication · 19260752 (PubMed) · PMC4016915 (PubMed Central)
  104. Genetic predictors of MEK dependence in non-small cell lung cancer. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, Ladanyi M, Gazdar A, Rosen N, Solit DB (2008) Cancer Res 68(22): 9375-83
    › Primary publication · 19010912 (PubMed) · PMC2649746 (PubMed Central)
  105. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W (2008) Clin Cancer Res 14(22): 7519-25
    › Primary publication · 19010870 (PubMed) · PMC2596620 (PubMed Central)
  106. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S (2008) Clin Cancer Res 14(21): 7060-7
    › Primary publication · 18981003 (PubMed) · PMC2596582 (PubMed Central)
  107. Somatic mutations affect key pathways in lung adenocarcinoma. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK (2008) Nature 455(7216): 1069-75
    › Primary publication · 18948947 (PubMed) · PMC2694412 (PubMed Central)
  108. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, Miller VA, Ladanyi M (2008) Clin Cancer Res 14(18): 5731-4
    › Primary publication · 18794081 (PubMed) · PMC2754127 (PubMed Central)
  109. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D, Levine R, Michel K, Thomas RK, Rusch VW, Ladanyi M, Pao W (2008) Cancer Res 68(14): 5524-8
    › Primary publication · 18632602 (PubMed) · PMC2586155 (PubMed Central)
  110. EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. Marks JL, Golas B, Kirchoff T, Miller VA, Riely GJ, Offit K, Pao W (2008) J Thorac Oncol 3(7): 805
    › Primary publication · 18594331 (PubMed)
  111. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, Huang CL, Bean J, Cheng AL, Pao W, Yang PC (2008) J Clin Oncol 26(16): 2745-53
    › Primary publication · 18509184 (PubMed)
  112. Constitutive activation of Raf-1 induces glioma formation in mice. Lyustikman Y, Momota H, Pao W, Holland EC (2008) Neoplasia 10(5): 501-10
    › Primary publication · 18472967 (PubMed) · PMC2373912 (PubMed Central)
  113. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Ladanyi M, Pao W (2008) Mod Pathol : S16-22
    › Primary publication · 18437168 (PubMed)
  114. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. Li AR, Chitale D, Riely GJ, Pao W, Miller VA, Zakowski MF, Rusch V, Kris MG, Ladanyi M (2008) J Mol Diagn 10(3): 242-8
    › Primary publication · 18403609 (PubMed) · PMC2329789 (PubMed Central)
  115. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH (2008) J Clin Oncol 26(9): 1472-8
    › Primary publication · 18349398 (PubMed)
  116. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE, Ladanyi M, Pao W (2008) J Thorac Oncol 3(2): 111-6
    › Primary publication · 18303429 (PubMed)
  117. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. Azzoli CG, Park BJ, Pao W, Zakowski M, Kris MG (2008) J Thorac Oncol 3(1): 84-93
    › Primary publication · 18166846 (PubMed)
  118. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W (2007) Proc Natl Acad Sci U S A 104(52): 20932-7
    › Primary publication · 18093943 (PubMed) · PMC2409244 (PubMed Central)
  119. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF (2007) J Clin Invest 117(12): 3846-56
    › Primary publication · 18060032 (PubMed) · PMC2096430 (PubMed Central)
  120. Characterizing the cancer genome in lung adenocarcinoma. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M (2007) Nature 450(7171): 893-8
    › Primary publication · 17982442 (PubMed) · PMC2538683 (PubMed Central)
  121. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, Pao W (2007) PLoS Med 4(10): e294
    › Primary publication · 17927446 (PubMed) · PMC2001209 (PubMed Central)
  122. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH, Miller VA (2007) Clin Cancer Res 13(17): 5150-5
    › Primary publication · 17785570 (PubMed)
  123. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Pao W, Ladanyi M (2007) Clin Cancer Res 13(17): 4954-5
    › Primary publication · 17785543 (PubMed)
  124. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. Regales L, Balak MN, Gong Y, Politi K, Sawai A, Le C, Koutcher JA, Solit DB, Rosen N, Zakowski MF, Pao W (2007) PLoS One 2(8): e810
    › Primary publication · 17726540 (PubMed) · PMC1950079 (PubMed Central)
  125. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA (2007) Cancer 110(3): 599-605
    › Primary publication · 17577220 (PubMed)
  126. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. Marks JL, McLellan MD, Zakowski MF, Lash AE, Kasai Y, Broderick S, Sarkaria IS, Pham D, Singh B, Miner TL, Fewell GA, Fulton LL, Mardis ER, Wilson RK, Kris MG, Rusch VW, Varmus H, Pao W (2007) PLoS One 2(5): e426
    › Primary publication · 17487277 (PubMed) · PMC1855985 (PubMed Central)
  127. BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models. Christiani DC, Pao W, DeMartini JC, Linnoila RI, Malkinson AM, Onn A, Politi KA, Sharp M, Wong KK, Kim K (2006) J Thorac Oncol 1(9 Suppl): S2-7
    › Primary publication · 17409996 (PubMed)
  128. Monitoring EGFR-mutant lung cancers by means of the blood. Pao W (2006) J Thorac Oncol 1(3): 199-200
    › Primary publication · 17409855 (PubMed)
  129. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Riely GJ, Politi KA, Miller VA, Pao W (2006) Clin Cancer Res 12(24): 7232-41
    › Primary publication · 17189394 (PubMed)
  130. Defining clinically relevant molecular subsets of lung cancer. Pao W (2006) Cancer Chemother Pharmacol : s11-5
    › Primary publication · 17093937 (PubMed)
  131. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W (2006) Clin Cancer Res 12(21): 6494-501
    › Primary publication · 17085664 (PubMed)
  132. Molecular on/off switch. Milton DT, Riely GJ, Pao W, Miller VA, Kris MG, Heelan RT (2006) J Clin Oncol 24(30): 4940-2
    › Primary publication · 17050880 (PubMed)
  133. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Milton DT, Azzoli CG, Heelan RT, Venkatraman E, Gomez JE, Kris MG, Krug LM, Pao W, Rizvi NA, Dunne M, Miller VA (2006) Cancer 107(5): 1034-41
    › Primary publication · 16878326 (PubMed)
  134. Oncogenes come of age. Varmus H, Pao W, Politi K, Podsypanina K, Du YC (2005) Cold Spring Harb Symp Quant Biol : 1-9
    › Primary publication · 16869733 (PubMed) · PMC1791364 (PubMed Central)
  135. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE (2006) Genes Dev 20(11): 1496-510
    › Primary publication · 16705038 (PubMed) · PMC1475762 (PubMed Central)
  136. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. Pham D, Kris MG, Riely GJ, Sarkaria IS, McDonough T, Chuai S, Venkatraman ES, Miller VA, Ladanyi M, Pao W, Wilson RK, Singh B, Rusch VW (2006) J Clin Oncol 24(11): 1700-4
    › Primary publication · 16505411 (PubMed)
  137. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA (2006) Clin Cancer Res 12(3 Pt 1): 839-44
    › Primary publication · 16467097 (PubMed)
  138. Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important? Riely GJ, Pao W (2005) Cancer Biol Ther 4(10): 1096-7
    › Primary publication · 16294020 (PubMed)
  139. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Lassman AB, Rossi MR, Raizer JJ, Razier JR, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, Holland EC (2005) Clin Cancer Res 11(21): 7841-50
    › Primary publication · 16278407 (PubMed)
  140. Erlotinib in lung cancer. Pao W, Ladanyi M, Miller VA, Lung Cancer Oncogenome Group (2005) N Engl J Med 353(16): 1739-41; author reply 1739-41
    › Primary publication · 16240471 (PubMed)
  141. Simple purification methods for an alphagalactose-specific antibody from chicken eggs. Cook CL, Pao W, Firca JR, Anderson BE, Fryer JP (2001) J Biosci Bioeng 91(3): 305-10
    › Primary publication · 16232994 (PubMed)
  142. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. Pan Q, Pao W, Ladanyi M (2005) J Mol Diagn 7(3): 396-403
    › Primary publication · 16049312 (PubMed) · PMC1867537 (PubMed Central)
  143. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ (2005) Proc Natl Acad Sci U S A 102(31): 11011-6
    › Primary publication · 16046538 (PubMed) · PMC1180625 (PubMed Central)
  144. Epidermal growth factor receptor mutations detected in tumors from Chinese "never smokers" with lung adenocarcinoma. Ren GP, Wang TY, Pan QL, Pao W, Huai J (2005) Chin Med J (Engl) 118(9): 769-71
    › Primary publication · 15899142 (PubMed)
  145. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. Pao W, Miller VA (2005) J Clin Oncol 23(11): 2556-68
    › Primary publication · 15767641 (PubMed)
  146. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) PLoS Med 2(3): e73
    › Primary publication · 15737014 (PubMed) · PMC549606 (PubMed Central)
  147. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE (2005) PLoS Med 2(1): e17
    › Primary publication · 15696205 (PubMed) · PMC545207 (PubMed Central)
  148. Practical management of patients with non-small-cell lung cancer treated with gefitinib. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA (2005) J Clin Oncol 23(1): 165-74
    › Primary publication · 15557594 (PubMed)
  149. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) Proc Natl Acad Sci U S A 101(36): 13306-11
    › Primary publication · 15329413 (PubMed) · PMC516528 (PubMed Central)
  150. Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt? Pao W, Miller VA, Venkatraman E, Kris MG (2004) J Natl Cancer Inst 96(15): 1117-9
    › Primary publication · 15292378 (PubMed)
  151. Serum levels of surfactant protein D are increased in mice with lung tumors. Zhang F, Pao W, Umphress S, Jakowlew S, Meyer AM, Dwyer-Nield LD, Takeda K, Gelfand EW, Fisher J, Malkinson AM, Mason RJ (2004) Chest 125(5 Suppl): 109S
    › Primary publication · 15136449 (PubMed)
  152. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT (2004) J Clin Oncol 22(6): 1103-9
    › Primary publication · 15020612 (PubMed)
  153. 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Pao W, Miller VA, Kris MG (2004) Semin Cancer Biol 14(1): 33-40
    › Primary publication · 14757534 (PubMed)
  154. Serum levels of surfactant protein D are increased in mice with lung tumors. Zhang F, Pao W, Umphress SM, Jakowlew SB, Meyer AM, Dwyer-Nield LD, Nielsen LD, Takeda K, Gelfand EW, Fisher JH, Zhang L, Malkinson AM, Mason RJ (2003) Cancer Res 63(18): 5889-94
    › Primary publication · 14522914 (PubMed)
  155. A protein knockdown strategy to study the function of beta-catenin in tumorigenesis. Cong F, Zhang J, Pao W, Zhou P, Varmus H (2003) BMC Mol Biol : 10
    › Primary publication · 14516475 (PubMed) · PMC222962 (PubMed Central)
  156. Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance. Pao W, Klimstra DS, Fisher GH, Varmus HE (2003) Proc Natl Acad Sci U S A 100(15): 8764-9
    › Primary publication · 12857957 (PubMed) · PMC166387 (PubMed Central)
  157. Epidural abscess and vertebral osteomyelitis caused by Listeria monocytogenes: case report and literature review. Khan KM, Pao W, Kendler J (2001) Scand J Infect Dis 33(9): 714-6
    › Primary publication · 11669234 (PubMed)
  158. Numerous eruptive lesions of panniculitis associated with group A streptococcus bacteremia in an immunocompetent child. Pao W, Duncan KO, Bolognia JL, Carroll CB, Hotez PJ, Bessen DE (1998) Clin Infect Dis 27(3): 430-3
    › Primary publication · 9770136 (PubMed)
  159. Primary gamma delta cell clones can be defined phenotypically and functionally as Th1/Th2 cells and illustrate the association of CD4 with Th2 differentiation. Wen L, Barber DF, Pao W, Wong FS, Owen MJ, Hayday A (1998) J Immunol 160(4): 1965-74
    › Primary publication · 9469460 (PubMed)
  160. Intrathymic delta selection events in gammadelta cell development. Passoni L, Hoffman ES, Kim S, Crompton T, Pao W, Dong MQ, Owen MJ, Hayday AC (1997) Immunity 7(1): 83-95
    › Primary publication · 9252122 (PubMed)
  161. Gamma delta T cell help of B cells is induced by repeated parasitic infection, in the absence of other T cells. Pao W, Wen L, Smith AL, Gulbranson-Judge A, Zheng B, Kelsoe G, MacLennan IC, Owen MJ, Hayday AC (1996) Curr Biol 6(10): 1317-25
    › Primary publication · 8939571 (PubMed)
  162. Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase. Mallick-Wood CA, Pao W, Cheng AM, Lewis JM, Kulkarni S, Bolen JB, Rowley B, Tigelaar RE, Pawson T, Hayday AC (1996) Proc Natl Acad Sci U S A 93(18): 9704-9
    › Primary publication · 8790395 (PubMed) · PMC38493 (PubMed Central)
  163. Germinal center formation in mice lacking alpha beta T cells. Dianda L, Gulbranson-Judge A, Pao W, Hayday AC, MacLennan IC, Owen MJ (1996) Eur J Immunol 26(7): 1603-7
    › Primary publication · 8766567 (PubMed)
  164. Germinal center formation, immunoglobulin class switching, and autoantibody production driven by "non alpha/beta" T cells. Wen L, Pao W, Wong FS, Peng Q, Craft J, Zheng B, Kelsoe G, Dianda L, Owen MJ, Hayday AC (1996) J Exp Med 183(5): 2271-82
    › Primary publication · 8642336 (PubMed) · PMC2192585 (PubMed Central)
  165. Syk tyrosine kinase required for mouse viability and B-cell development. Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T (1995) Nature 378(6554): 303-6
    › Primary publication · 7477353 (PubMed)
  166. Influence of site of expression on the fetal gamma delta T-cell receptor repertoire. Kyes S, Pao W, Hayday A (1991) Proc Natl Acad Sci U S A 88(17): 7830-3
    › Primary publication · 1652766 (PubMed) · PMC52397 (PubMed Central)